London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Started: Silverblade, 8 Jul 2022 10:05
Last post: Silverblade, 8 Jul 2022 10:05
First time I have seen an EBITDA forecast for 2022 performance - from Oryx " The company's management team continued to deliver on the stated strategy of taking cost out of the business while driving sales through its international distributor-led model. The company is now profitable for the first time and expects to generate at least £4.1 million of EBITDA in 2022, a remarkable achievement given the group had lost £25 million of EBITDA as recently as 2019. The balance sheet is robust with circa £13.5 million net cash and management have expressed confidence in Circassia's ability to outperform market expectations. "
If the business can continue to grow its revenue through it low overhead sales model this bodes well for the future. SB
Started: Silverblade, 10 Jun 2022 16:37
Last post: Schlum, 5 Jul 2022 18:02
True, but the mkt cap. Of £130m looks a stretch.
Looks like Spreadex (or their clients) exited 1/3 of their position on Friday 1st - explains the 4.375m buy/sell - possibly helped by the announcement we have $10m in cash due from Beyond Air over next 2 years with a potential further $6m in royalties. Update expected next week - should be over £15m revenue in first half; c.£14m+ cash in bank; money flowing from beyond air; and hopefully a positive look ahead for the second half of the year. SB
Hi all, I must be missing something, but does anyone understand the recent significant share price fall here? Thanks
Good point hectordog - although it is possible that there are a number of parties that sit beneath the 'position' - in which case individually they not would trigger a declaration above 3%. Last previous disclosed short position was closed out in 2019 - so perhaps this is a long position with spreadbet acting as the broker? Question is - what has prompted a 14m CFD share trade - normal business aside? SB
Surely it will likely be a professional client of Spreadex that is the underlying 'investor'? I can't believe that Spreadex is investing on its own account. If I am right, then the underlying account holder should rightly be named.
Started: Silverblade, 22 Mar 2022 10:22
Last post: sailorgirl, 15 May 2022 18:43
Pretty obvious that the AGM statement was a ‘for sale’ sign. The business has been cleaned up, is making good gross profits and generating cash. When Christopher Mills did that video interview of the companies he had investments in a while ago (I think he has 29% of CIR) he speculated that a larger company might buy it to consolidate its business with their own and eliminate duplicated overheads. Makes a lot of sense and could happen sooner than we think.
Does raise the question - what are the expectations!! Any ideas? H1 revenue could be c.£16m based on the AGM statement - running costs are not clear given the head count savings were not expected to impact until 2022 - and clearly both revenue needs to increase and costs need to come down as we will not have the benefit of a £4m tax credit in 2022 to offset the group trading loss. Going in the right direction though - growing, cash in bank, positive cash flow, potential beyond air settlement upside if lungfit gets FDA - but its going to take something quite special to hit the 63p Dec 2022 options bonus for our executive chairman. SB
only materially ahead of expectations! At least we're not being caned for it yet in this stupid market
Couple of mighty meaty purchases from directors helps steady the ship's drift
Nothing of any real note from a first pass. Pretty much just a one trick pony now - niox or bust! If the company is being fully transparent on its cost of sales and reached a point where further cost savings are now limited - the only route to a profitable business is to increase niox sales - with US and Asia the two key target markets. If we can maintain year to date sales growth of 20% (clinical focus which accounts for 85%+ of revenue), this would take us close to pre-pandemic sales level (£34m) for current year - and should deliver an actual trading profit - no point in a 68% gross margin when costs wipe all of that margin out. Good to have plenty of cash in back with future positive cash generation and beyond air royalties helping build that position. Now we are a clean and viable business I wonder if the team have had any enquiries. SB
shares are nicely set up to rally into the results in a few weeks...expecting a continuation of the strong trading and should push on into the 60's triggering the windfall for management..
I would agree - the 10 days appear to relate to the period prior to the options being granted ie that was how the options price of c.63p was calculated. Good spot. Based on where we are the only realistic chance of getting to that price by Dec is a takeover imo. SB
I read it as SP has to exceed 63p for 30 consecutive days (not 10 days) or a liquidity event above that level. Could be wrong.
or a liquidity event......which may be the best opportunity to reach that price this year. SB
Thank you Taltbong. So essentially the sp has to reach 63p for ten consecutive days leading up to 5th Dec this year.
I think that looks doable. Just need this covid malarkey to buzz off.
Started: wiseys, 25 Jan 2022 16:30
Last post: wiseys, 25 Jan 2022 16:30
wow!...someone just paid over the asking price for 18m shares!...42.3p
Started: Betafail, 13 Jan 2022 07:36
Last post: TaltBong, 13 Jan 2022 07:53
Superb update. May the SP rise continue. Holding long term here and it will be interesting to follow the story and see if the much talked about buy out by a big player happens.
I can see why people we're buying in yesterday, could have been a leak
Started: hectordog, 1 Jan 2022 16:20
Last post: Betafail, 12 Jan 2022 16:21
Looks like there's been a lot of block trades today so could be an institution getting in - could get a TR-1 drop very soon.
This is just speculation though, I could be completely wrong
Nice move today! Trading update might be tomorrow based on last year, or very soon.
Suspect might be v good news....................
Just look at all those buys today!
Didn't I just tell ya?
Certainly looks that way hectordog. Interesting rise on total voting rights RNS. One of the few brighter stars in small caps at the moment.
Likely to be some fun with CIR in January as a trading update should be due around the 13th. My guess is that it will be good……..
Started: Betafail, 12 Jan 2022 13:50
Last post: Betafail, 12 Jan 2022 13:50
We're looking at over 10x average volume and the day's not even finished
Last post: Betafail, 12 Jan 2022 10:52
Price has randomly started to rocket
Started: wiseys, 30 Sep 2021 14:51
Last post: ian67, 1 Oct 2021 14:00
Nice interview,following the money....
some large buy orders have gone through by the looks of it....shares could kick on to 50p
Started: andmillsy, 16 Sep 2021 08:32
Last post: BruceJamieson, 23 Sep 2021 09:26
Richard Griffiths &co have 29.9% that is all you need to know
Batterseafish
Pe is minus .4. Quite irrelevant
Would appear an Investment Bank opinion ( Singers). Why are you knocking it given the analysis and projections stated?
Why 60p? Isn’t it on a high prospective pe already?
Singers have upgraded 2022 EPS by 215% to 0.5p and 2023 by 22.6% to 1.2p....huge..shares should be 60p
Chris Mills' Harwood Capital increasing their holding to 18.55%
Started: TaltBong, 17 Sep 2021 08:14
Last post: fairdealer20, 17 Sep 2021 08:56
Following yesterday's results, can only be a strong buy signal. Excellent news to all SH's
Always good to see directors getting more "skin in the game"
Started: ImaWinner, 9 Aug 2021 12:28
Last post: ImaWinner, 9 Aug 2021 12:28
This is getting to be interesting now. Am sure you have seen PM re-table $1Bn plus offer for VEC as part of their 'Beyond Nicotine' strategy, this being in competition to the PE bid from Carlyle. IMHO a cigarette maker does not sit well with a healthcare company nor its clients, but may be good for this stock sentiment, as combining an asthma product company with an asthma diagnostic company is a reasonable idea. This may have somewhere to run still.
Last post: Batterseafish, 9 Aug 2021 12:23
Following in steps of Vectura?
inflection point reached....60p PT seems fair..!
Started: hectordog, 13 Jul 2021 08:23
Last post: TaltBong, 13 Jul 2021 10:01
Not that I have any intension of selling I hasten to add
Up over 33p to sell and rising
Wow, what a turnaround. EBITDA positive!
Well on course for eventual sale at much higher price than 30p!!
Started: ynwa1, 26 Apr 2021 16:13
Last post: sam4224, 27 Jun 2021 17:21
So very clear who misread themarket
possibly true but invested in ferro alloy , proteome sciences, and bacanora so fortunately turned out really well. had best week in 18 months. cant quite believe it. good luck all
Some heavy trading over the last week or so
sam4224 got out way too early. Misread the market completely
when this pops !
Started: BruceJamieson, 26 May 2021 09:05
Last post: BruceJamieson, 26 May 2021 09:05
good to see this settled see today RNS
Last post: hxharry, 26 Apr 2021 13:31
Hopefully finally breaking out of the 20's. I've been accumulating for a couple of years now and waiting for this uplift. For me personally I will be holding, like the director commitment.
there is no point an individual shareholder contacting a company. they will not tell you anything as that would be unfair and illegal
Counting my blessings got out of this company. Held for two years and during that time it lost a product it has not gone after through the courts, handed back two products, and cut debt but also research. Very limited product portfolio with cost cutting the only corporate goal. Tried to engage the company as a reasonable size shareholder. Emails and phone calls ignored every time.
Started: Batterseafish, 20 Apr 2021 14:34
Last post: Batterseafish, 20 Apr 2021 14:34
I wonder if this company will capitalise on this news.
Started: BruceJamieson, 6 Apr 2021 19:04
Last post: BruceJamieson, 6 Apr 2021 19:04
on the LSE home page. Surprised my posting removed. Hardly contentious
Started: BruceJamieson, 30 Mar 2021 17:02
Last post: BruceJamieson, 6 Apr 2021 17:09
more leadership purchases mentioned on LSE home psge
more leadership purchases mentioned on LSE home psge
I see the recent 25p share purchases by some of the major shareholders as a positive
i see Richard Griffiths has got 6 million and Lombard still supportive, bullish
Does anyone know what is happening re US court case
Started: sam4224, 24 Mar 2021 08:30
Last post: sam4224, 24 Mar 2021 08:30
Have reduced before but thinking of getting out. Seem to be focused on cost cutting as a strategy rather than a strategy for building the company. Thought the comment concerning beyond air a year down stream was pathetic. Clearly all talk and no trousers. Happy to be convinced but am of the opinion much better companies to invest in.
Started: Chrisbish, 17 Mar 2021 09:29
Last post: Coffee73, 17 Mar 2021 12:29
Hopefully EBITDA breakeven will be in sight.
Yes, year end figures out on 24th March so hoping for some decent figures next week. The last trading update in January suggested that cost savings had been better than anticipated - but we will see.
Shares have seen a slow but steady rise over the last few weeks. Anyone have an opinion for short term prospects. About to test a new high.
Last post: BruceJamieson, 5 Mar 2021 12:46
help! grammarian needed, not urgent
??
!!